1. Medtech Insight
  2. >>Policy & Regulation

Stryker In Neverland: Firm Ups Focus On Averting Avoidable Events With Sage Acquisition

Stryker will pay nearly $2.8 billion to buy Sage Products and its portfolio of products to prevent health care "never events," which hospitals are increasingly motivated to avoid.

Stryker Corp. will pay $2.775 billion in cash for Sage Products Inc. to expand its portfolio of disposable products that can help hospitals reduce the incidence of so-called "never events," such as hospital-acquired infections.

Insurers are increasingly introducing financial incentives for hospitals to avoid preventable conditions, which are both detrimental to patients and very costly to the health care system. Stryker's Feb. 1-announced purchase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.